Headache & Migraine
Conference Coverage
Adding CGRP to Botox is safe and effective for migraine prevention
Conference Coverage
Commonalities challenge the threshold of high-frequency episodic and low-frequency chronic migraine
Study reports commonalities between high-frequency episodic and low-frequency chronic migraine, raising questions about current diagnostic...
Latest News
Daily Recap: Lung ultrasound helps diagnose COVID-19 in kids, first treatment approved for adult-onset Still’s disease
Lung ultrasound has “high concordance” with radiologic findings in children with COVID-19 and offers benefits over other imaging techniques.
Conference Coverage
NSAID/triptan combination improves treatment-resistant migraine
A combination of rizatriptan and meloxicam formulated to improve oral absorption led to better outcomes than rizatriptan alone.
Conference Coverage
CGRPs in real world: Similar efficacy, more AEs
A real-world study of monoclonal antibody agents reported comparable efficacy but more adverse events than clinical trials.
Conference Coverage
Intranasal DHE shows promise in migraine
New formulation of DHE joins other efforts to improve delivery of existing drugs.
Latest News
Daily Recap: COVID-19 comorbidity death toll; screen all women for anxiety
Volunteer “street medics” -- nursing students, veterinarians, doctors, trauma surgeons, security guards, ski patrollers, nurses, wilderness EMTs,...
Conference Coverage
Persistent posttraumatic headache risk factors confirmed
An analysis of 300 patients with posttraumatic headache reveals some long-suspected risk factors of persistent headache, but also a high...
Conference Coverage
Few patients with migraine clear barriers to optimal care
Less than 8% of patients with episodic migraine and less than 2% of patients with chronic migraine were able to overcome four key treatment...
Conference Coverage
Population study supports migraine–dementia link
Migraine with aura confers a significantly higher risk of dementia, according to preliminary findings from a population-based cohort study in...
Conference Coverage
Galcanezumab looks promising for treatment-resistant migraine
The monoclonal antibody reduced the mean number of monthly migraine days in a 3-month open-label extension of the phase 3 CONQUER study.